BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 24360358)

  • 1. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
    Limaverde-Sousa G; Sternberg C; Ferreira CG
    Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic agents in cancer therapy.
    Lenz HJ
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
    Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
    Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic agents and targets: A perspective.
    Teicher BA
    Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity.
    Kelly RJ; Darnell C; Rixe O
    Cancer J; 2010; 16(6):635-42. PubMed ID: 21131797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.
    Gille J
    Exp Dermatol; 2006 Mar; 15(3):175-86. PubMed ID: 16480425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond bevacizumab: antiangiogenic agents.
    Rogosin S; Sandler AB
    Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor: biology and therapeutic applications.
    Ho QT; Kuo CJ
    Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic therapy and surgical practice.
    John AR; Bramhall SR; Eggo MC
    Br J Surg; 2008 Mar; 95(3):281-93. PubMed ID: 18278790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
    Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
    Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumoral angiogenesis: review of the literature.
    Khosravi Shahi P; Fernández Pineda I
    Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.